PRESS RELEASE DUBLIN.

PRESS RELEASE DUBLIN,Aug. 31, 2015/PRNewswire/ –Allergan plc, a leading global pharmaceutical company, announced that it has successfully finished the acquisition ofNaurex Inc today., a clinical-stage biopharmaceutical company developing transformative therapies for complicated disorders of the central nervous system, including unhappiness.Allerganacquired Naurex for a$560 millionupfront payment net of cash acquired,$460 millionof which is certainly payable upon the closing of the acquisition and$100 millionof which can be payable simply by January of 2016, in addition to potential R&D sales-threshold and success-based milestone payments. The acquisition of Naurex enhances our ability to become among the leaders in the development of novel, game-changing therapies in mental health.After the extraction of DNA, polymerase-chain-reaction amplification and sequencing were performed on both tooth samples for the region flanking the R304 site in four different reactions. All eight products included the heterozygous c. To investigate whether the four family members carry the c., and Body 1 in the Supplementary Appendix). We found a single common haplotype in an area between microsatellite markers Chr11-64-TG-110 and D11S987 spanning 2.68 megabases shared among all five lineages. The shared haplotype might extend from Chr11-64-AC-110 to Chr11-67-TG-107, covering 3.50 Mb, but to be conservative, we used the minimal shared area in our calculations.